Trial Profile
A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2024
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Antithymocyte globulin; Ciclosporin; Ciclosporin
- Indications Aplastic anaemia
- Focus Pharmacokinetics
- Acronyms ESCALATE
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 06 Feb 2024 Planned End Date changed from 9 Apr 2025 to 29 Jan 2025.
- 20 Mar 2023 Planned End Date changed from 8 Mar 2025 to 9 Apr 2025.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition